Table 2.

Prognostic factors in IDH-mutant astrocytoma: univariate and multivariate analyses

Entire cohort, univariate analyses	Hazard ratio	p value	95% CI
CNS WHO grade
2 (ref)	–
3	2.35	<0.001	1.47–3.76
4	4.14	<0.001	2.60–6.57
Age (years)
> 40 versus ≤ 40 (ref.)	1.61	0.013	1.10–2.34
KPS
<80 versus ≥80 (ref.)	2.55	<0.001	1.53–4.25
Surgery
No total versus total (ref.)	1.73	0.017	1.10–2.73
MGMT promoter status
Methylated versus unmethylated (ref.)	1.64	0.043	1.01–2.64
IDH mutation status
IDH1-R132H versus other IDH1 or IDH2 mutations (ref.)	1.66	0.169	0.81–3.40
CDKN2A deletion status
Homozygous versus no homozygous (ref.)	6.04	<0.001	2.90–12.56
LINE-1 methylation status
≤77 versus >77% methylated alleles (ref.)	3.54	<0.001	2.25–5.56

Entire cohort, multivariate analyses	Hazard ratio	p value	95% CI
CNS WHO grade
2 (ref)	–
3	3.09	0.007	1.36–7.00
4	1.42	0.577	0.42–4.80
Age (years)
> 40 versus ≤ 40 (ref.)	1.58	0.098	0.92–2.72
KPS
<80 versus ≥80 (ref.)	1.17	0.627	0.621–2.21
Surgery
No total versus total (ref.)	2.61	< 0.001	1.49–4.58
MGMT promoter status
Methylated versus unmethylated (ref.)	1.03	0.936	0.54–1.96
IDH mutations status
IDH1-R132H versus other IDH1 or IDH2 mutations (ref.)	1.85	0.165	0.78–4.39
CDKN2A deletion status
Homozygous versus no homozygous (ref.)	3.74	0.008	1.41–9.92
LINE-1 methylation status
≤77 versus >77% methylated alleles (ref.)	3.39	0.025	1.17–9.85